Benzinga | Jan 6, 2022 05:57AM EST

Morgan Stanley Initiates Coverage On Nautilus Biotechnology with Equal-Weight Rating, Announces Price Target of $8

Morgan Stanley analyst Tejas Savant initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Equal-Weight rating and announces Price Target of $8.